Penn in the News

Richard Berk of the School of Arts & Sciences and the Wharton School is quoted about providing data to help keep policymakers and the public more aware of crime-related statistics.

Michael Perlis of the Perelman School of Medicine suggests that placebos, currently used mainly for control groups in clinical trials, may be worth another look for treatment and for chronic illnesses; they might be a key to increasing a drug’s lifetime effectiveness.

Marvell Technology Group Ltd. convinced a federal appeals court to reverse most of a $1.54 billion damage award to Carnegie Mellon University in a closely watched patent case. But the U.S. Court of Appeals for the Federal Circuit on Tuesday affirmed that Marvell infringed the two patents at issue in the case, which cover technology related to computer disk drives. The court ruled that Marvell must pay the university at least $278.4 million, and ordered a new trial on issues that could increase that award.

Charlie Johnson of the School of Engineering and Applied Science and the School of Arts & Sciences is mentioned as a physicist and director of Penn’s Nano/Bio Interface Center.

Leaders of Lancaster County's largest health system have repeatedly cited the need to move the industry away from its current fee-for-service model as a key factor in their decision to become part of Philadelphia-based Penn Medicine.

Marie Gottschalk of the School of Arts & Sciences comments on Michelle Alexander’s book The New Jim Crow.

Iwan Barankay of the Wharton School says, “Performance-related pay, of which bonuses are an example, will become more and more prevalent.”

Over the past several years, they could hardly have had bigger news to report. The young journalists at the Cavalier Daily, the University of Virginia’s student newspaper, covered stories that made international headlines: murder, leadership, crises, allegations of rape and racial attacks. But even as its student reporters were going after the news, the paper’s business side was struggling.